AriBio’s mirodenafil candidate, AR1001 (a PDE5 inhibitor) met it's primary endpoint in a prespecified subpopulation in the Phase 3 Polaris-AD trial, representing a 31% slowing of clinical symptoms
aribio.aribiogroup.com/irpr/pressre...
AriBio’s mirodenafil candidate, AR1001 (a PDE5 inhibitor) met it's primary endpoint in a prespecified subpopulation in the Phase 3 Polaris-AD trial, representing a 31% slowing of clinical symptoms
aribio.aribiogroup.com/irpr/pressre...
📖 rdcu.be/mTnvkD3Wyj2a
#SexualMedicine #IJIR
📖 rdcu.be/mTnvkD3Wyj2a
#SexualMedicine #IJIR
#Sante #Troubles
www.dementiaresearcher.nihr.ac.uk/job/clinical...
www.dementiaresearcher.nihr.ac.uk/job/clinical...